Member Info for Yorkshirepragma

And to illustrate the global testing increase, as taking ‘ control’ becomes the most relevant tactic against COVID, see table below. @2/9/20.
https://ourworldindata.org/coronavirus-testing#testing-for-covid-19-background-the-our-world-in-data-covid-19-testing-dataset
Avacta now likely to need all that production (and more elsewhere). Revenue? Share cap going forward? LARGE
GLA

It’s said that the ‘Pharms. Business ‘, relies on Good Science, process and patience... only the last needed here I’d respectfully suggest.
GLA

https://www.statista.com/statistics/1028311/price-earnings-in-the-health-and-pharmaceuticals-sector-in-europe/

FYI

https://books.google.co.uk/books?id=HZvlLRuZnaMC&printsec=frontcover&redir_esc=y#v=onepage&q&f=false

Likely Revenue( or live rev.) x15= m.cap.
For Avacta at year end...?

https://ourworldindata.org/coronavirus-testing#how-many-tests-are-performed-each-day

Test is antibody based. The science to date shows antibody formation rev Covid is weak. Odd this test should therefore be seen as intuitive for Covid? It has a place but not as best accurate test. Finer test fit Covid directly will of course do this .

RK, thanks for developing this train of thought... it’s highly relevant to what may appen in due time....my guess £1.5bn on successful LFT delivery...rising if the USA political sphere get hold...
Nuff said..
Cheers

PSB , the recent COVID test driven Abbot uplift @ £ 15bn m.cap added value ,bodes well for ‘some significant’ re rate in Avacta. Everyone to their own.......

Inference of the ‘added value’ of a COVID test scheme ,may well be seen on confirmation of test competence. USA interest driven by Cytiva PR is probablY ‘warming up’ right now.
GLA

RK, That’s a ca £15bn uplift in m.cap. from the COVID test value. In Avacta terms that equivalent would “do us proud?.. “.

Stateside takeup will determine the outcome here... howdy doody time ... 14.30 Greenwich?

GLA

As an old bold” pharma bod... it’s imminent I suspect . Prime data process 2 -4weeks but with pressures here much less . LFD same , it’s about results vis. device type.
Gla

Good summary... and for a share such as this common sense will win out. Yesterday’s production company tweet signals to all.

And revenue from this action...AS used a good descriptor at his interview earlier on in the dev. process...but events would say ‘ huge revenue’. ...and imminent...!
GLA

https://ourworldindata.org/grapher/daily-tests-per-thousand-people-smoothed-7-day

Increasing....
GLA

Couldn’t agree more .. “ moonshot “ will create a singular robust revenue stream in £Xm’s / month.
GLA

Manufacturing will be readily organised, only pinch point will be manufacturing machines availability However Engineering ingenuity to deliver is renowned...all covered I suspect.

& Avacta MCAP after having contributed to the process of eradication...I wonder?

&.....a phob lwc i bawb...

RK, agreed a good progression towards higher valuation. In terms of Tesla levels ,you never know . The Affimer technology could achieve notoriety following LFT completion,
Furthermore Cytiva PR although somewhat ‘quiet’, as many pharms. majors tend to be, might see themselves in the limelight.
USA perception of the successful application here could see this take off. It will be the” rate determining step” I suspect...here’s to a ++1bn val. ...who knows?
Nos da..